SUMMIT, N.J., September 15, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today announced new data that will be presented at the European Scientific Working Group on Influenza (ESWI) Conference taking place from 17-20 September 2023 in Valencia, Spain. Data derived from a variety of studies, including real-world evidence, economic and cost effectiveness modelling, and clinical studies across seasonal and pandemic influenza, will be shared as poster and oral presentations.

"At CSL Seqirus, public health protection is at our core and is what drives us to safeguard at-risk communities against seasonal and pandemic influenza threats," said Raja Rajaram, M.D., Head of Global Medical Strategy, CSL Seqirus. "Delivering on our promise means continually gathering and analyzing data to assess the value and impact of our vaccines, and we look forward to sharing results from many of these studies at ESWI that emphasize the national, regional and global impact.”^1,2

In addition, on 20 September, at 9:15-10:15 CEST, the 3^rd edition of the Young Scientist Vaccine Innovation Award will be presented to an emerging scientist to recognize exceptional research in the field of vaccine development. CSL Seqirus is a proud supporter of these awards as part of their commitment to innovation and superior performance through helping to foster the next generation of scientists.

Oral and Poster Presentations include:

• Development of Self-Amplifying mRNA Based H2N3 Pandemic Vaccine that is Cross Reactive with Improved Safety Features. Abstract. Oral presentation, September 18, 2023, 14:10 - 15:45.
• Influenza B Virus Neuraminidase: Antigenic evolution and antibody responses​. Abstract. Oral presentation: 10:45 - 12:20, September 18, 2023.
• Superior Effectiveness of Cell-Based Versus Egg Based Quadrivalent Influenza Vaccines Against Outpatient Test Confirmed Influenza Over Three Consecutive Seasons in the United States. Abstract. Oral presentation Exhibition, September 19, 2023, 10:45 - 12:20, Auditorium 1 - Plenary Hall.
• Effectiveness of Adjuvanted vs High-dose Trivalent Influenza Vaccine (aTIV vs HD TIV) in Individuals who are at High Risk of Influenza Complications or Poor Immune Response During the US 2019-2020 Influenza Season: Poster ID 676. 
• Estimating the Impact of Influenza Vaccination on Acute and ICU Hospital Bed Usage in an Influenza Season Under Endemic Covid-19 in France. Poster ID 197.
• Cost-Effectiveness of the Adjuvanted Quadrivalent Influenza Vaccine in the Belgian Elderly Population.​ Poster ID 196.
• Influenza Immunization and Anti-Neuraminidase Antibody Responses for the 2022 Southern Hemisphere Season (Encore). Poster ID 358
• Immune Responses to Combination Vaccines including RNA and Protein Platforms. Poster ID.
• Epizootic & Zoonotic Influenza Surveillance A Vital Component of Rapid Pandemic Response. Poster ID 461.
• Healthcare Resource Use and Complications Among Adults with an Influenza Related Medical Encounter: 2015-2020 Influenza Seasons in the United Sates. Poster ID 195.
• Circulation and Seasonality of Epidemics of Influenza, RSV and Other Respiratory Viruses Before, During, and After the COVID-19 Pandemic: A Global Overview Based on the WHO FluNet Database​. Poster ID 236.
• Lineage-Specific Antibody Titers Against Influenza B Virus Haemagglutinin Explain Birth Cohort-Specific Epidemiology. Poster ID 314.
• Mapping the risks of avian influenza outbreaks across Europe via machine learning. Poster ID 249.

To view the full ESWI program online, please visit: https://www.eswiconference.org/

About Seasonal Influenza
Influenza is a frequently occurring, contagious seasonal respiratory disease that may cause severe illness and life-threatening complications in some people.³  Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases, death.³  Because transmission of influenza viruses to others may occur before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others.³ Estimates from the Centers for Disease Control and Prevention (CDC) report that during the 2019/20 influenza season, there were an estimated 300,000-650,000 influenza-related hospitalizations in the U.S.⁴ The CDC recommends annual vaccination for individuals aged 6 months and older, who do not have any contraindications.⁵ Since it takes about two weeks after vaccination for antibodies to develop in the body that help protect against influenza virus infection, it is recommended that people get vaccinated before influenza begins spreading in their community.⁵ The CDC recommends that people get vaccinated by the end of October.⁵

About Pandemic Influenza
Influenza is a contagious airborne respiratory disease.^6,7 Pandemic flu occurs when a novel strain emerges that infects people, spreads easily from person-to-person, and to which most people do not have immunity.⁶ The risk of influenza-associated morbidity and mortality is greater with pandemic influenza than with seasonal influenza because there is likely to be little or no pre-existing immunity to the novel virus in the human population.⁸ The timing and severity of pandemic influenza is unpredictable, four influenza pandemics have occurred over the past century, with the 1918 pandemic being the most severe in recent history, estimated to have killed up to  100 million people worldwide.⁹ Strain-specific pandemic influenza vaccines are manufactured in response to the declaration of a pandemic. Pre-pandemic (also called zoonotic) influenza vaccines are developed in the inter-pandemic period to help protect against influenza strains with pandemic potential; these vaccines can be deployed under government instruction to mitigate the risk of an outbreak or provide a first line of defense in advance of a pandemic vaccine if a pandemic were to be declared.¹⁰

About CSL Seqirus
CSL Seqirus is part of CSL (ASX:CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus offers a broad portfolio of differentiated influenza vaccines worldwide.

For more information about CSL Seqirus, visit CSLSeqirus.com.

About CSL
CSL (ASX:CSL) (USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL.

For more information about CSL, visit www.CSL.com.

Intended Audience 
This press release is issued from CSL Seqirus in Summit, New Jersey, USA and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved CSL Seqirus products may vary from country to country. Please consult your local regulatory authority on the approval status of CSL Seqirus products.

Forward-Looking Statements 
This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. 

MEDIA CONTACT
Em Dekonor
+44 (0)7920500496
Emmanuella.Dekonor@seqirus.com

GL-NOPR-23-0007 | September 2023